Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.52 |
| ▸ | WDR5 | P61964 | 9/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | GNA11 | P29992 | 1/20 | 0.32 |
| ▸ | GNAQ | P50148 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105936 | 0.90 | CENPE (0.66) | CENPEWDR5S1PR1 | |
| SCHEMBL2105179 | 0.90 | CENPE (0.66) | CENPEWDR5S1PR1 | |
| SCHEMBL13161860 | 0.81 | CENPE (0.42) | CENPEWDR5S1PR1 | |
| SCHEMBL3463028 | 0.81 | CENPE (0.42) | CENPEWDR5S1PR1 | |
| SCHEMBL13183920 | 0.79 | CENPE (0.71) | CENPE | |
| SCHEMBL13637353 | 0.78 | CENPE (0.53) | CENPES1PR1 | |
| SCHEMBL13183958 | 0.77 | CENPE (0.69) | CENPE | |
| SCHEMBL13183953 | 0.77 | CENPE (0.57) | CENPE | |
| SCHEMBL13183922 | 0.77 | CENPE (0.68) | CENPEWDR5 | |
| SCHEMBL13184027 | 0.77 | CENPE (0.68) | CENPEWDR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885WDR5 1620/4885AVPR1B 4801/4885 |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 54/4885WDR5 1620/4885AVPR1B 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.